Blue-Zone Technologies signs agreement with Respirair Global
by CM Staff
As part of its manufacturing process, Respirair uses anesthetic gases to calibrate its vaporizers, but the anesthetic gases used for the calibration process are vented into the atmosphere unabated.
TORONTO — Blue-Zone Technologies Ltd., a Canadian cleantech pharmaceutical company that leverages globally-patented technology to capture waste anesthetic gases (WAGs) from healthcare facilities, announced it has signed an agreement with Respirair Global LLC to install its patented capture technology in Respirair’s manufacturing facility. Respirair is a U.K.-based manufacturer of anaesthesia vaporisers and accessories.
As part of its manufacturing process, Respirair uses anesthetic gases to calibrate its vaporizers, but the anesthetic gases used for the calibration process are vented into the atmosphere unabated. These WAGs, which are recognized as long-term health hazards and have a global warming potential of up to 6,810 times that of CO2, are about seven times heavier than air and linger near ground level. Under the terms of this novel agreement, Blue-Zone will install its proprietary, globally-patented technology, Centralsorb® Canister System (CCS), to capture WAGs at Respirair’s facility before they are vented into the community.
“The installation at Respirair marks our first contract with an anesthesia machine manufacturer and aligns well with the mission of both companies to create greener facilities,” said Kipton Lade, CEO of Blue-Zone Technologies. “At Blue-Zone, we are continually looking to provide creative solutions that help organizations reduce the GHG footprint for a positive impact on the environment and the communities they serve. We are excited to partner with Respirair to help them achieve their green objectives.”
As part of the agreement, Blue-Zone will also act as U.S. sales agent for Respirair, selling their vaporisers to the American healthcare market.
